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Multiple mechanisms mediating carbon monoxide
inhibition of the voltage-gated K+ channel Kv1.5
Moza M Al-Owais1, Nishani T Hettiarachchi1, John P Boyle1, Jason L Scragg1, Jacobo Elies1,3, Mark L Dallas1,4, Jon D Lippiat2,
Derek S Steele2 and Chris Peers*,1
The voltage-gated K+ channel has key roles in the vasculature and in atrial excitability and contributes to apoptosis in various
tissues. In this study, we have explored its regulation by carbon monoxide (CO), a product of the cytoprotective heme oxygenase
enzymes, and a recognized toxin. CO inhibited recombinant Kv1.5 expressed in HEK293 cells in a concentration-dependent
manner that involved multiple signalling pathways. CO inhibition was partially reversed by superoxide dismutase mimetics and by
suppression of mitochondrial reactive oxygen species. CO also elevated intracellular nitric oxide (NO) levels. Prevention of NO
formation also partially reversed CO inhibition of Kv1.5, as did inhibition of soluble guanylyl cyclase. CO also elevated intracellular
peroxynitrite levels, and a peroxynitrite scavenger markedly attenuated the ability of CO to inhibit Kv1.5. CO caused nitrosylation of
Kv1.5, an effect that was also observed in C331A and C346A mutant forms of the channel, which had previously been suggested as
nitrosylation sites within Kv1.5. Augmentation of Kv1.5 via exposure to hydrogen peroxide was fully reversed by CO. Native Kv1.5
recorded in HL-1 murine atrial cells was also inhibited by CO. Action potentials recorded in HL-1 cells were increased in amplitude
and duration by CO, an effect mimicked and occluded by pharmacological inhibition of Kv1.5. Our data indicate that Kv1.5 is a
target for modulation by CO via multiple mechanisms. This regulation has important implications for diverse cellular functions,
including excitability, contractility and apoptosis.
Cell Death and Disease (2017) 8, e3163; doi:10.1038/cddis.2017.568; published online 2 November 2017
Kv1.5 is a rapidly activating, voltage-gated K+ channel
encoded by KCNA5 that inactivates slowly and
incompletely.1 Distribution of Kv1.5 is widespread: it is
expressed in various cell types in the central nervous
system2,3 and is implicated in certain types of cancers.4
Kv1.5 is, however, perhaps best studied in the cardiovascular
system. Its expression/activity is associated with increased
apoptosis in endothelial and smooth muscle cells.5,6 In
vascular smooth muscle cells (VSMCs) of the pulmonary
vasculature, it is of particular importance to hypoxic pulmonary
vasoconstriction7–9 and in the development of pulmonary
arterial hypertension (PAH).10–12 Indeed, Kv1.5 expression is
reduced in PAH patients13 and patients with idiopathic PAH
possess important single-nucleotide polymorphisms in
KCNA5, which encodes Kv1.5.14,15 In the systemic circulation,
Kv1.5 also contributes to repolarization of the VSMC
membrane potential, limiting Ca2+ entry and hence vascular
tone.16–18 A recent study employing Kv1.5− /−mice has shown
that this channel is essential for balancing coronary blood flow
with metabolic demands of the working myocardium.19
In the heart, Kv1.5 expression is largely confined to the atria
where it is responsible for the ultrarapid outward current, IKur, the
major repolarizing current that is active throughout phases 1–3
of the atrial action potential (AP).20,21 Targeting of Kv1.5 activity/
expression is currently regarded as a promising therapeutic
approach to the treatment of atrial fibrillation (AF).22–25
Given thewidespread importance of Kv1.5 in the cardiovascular
system and elsewhere, it is perhaps unsurprising that it is
regulated via numerous posttranslational modifications,
including ubiquitination,26 sumoylation,26 palmitoylation,27
phosphorylation28,29 and nitrosylation.30 An additional means
of regulation is via its sensitivity to reactive oxygen species
(ROS). For example, tonic ROS production by mitochondria or
NADPH oxidase (Nox 4) sustains Kv1.5 activity and keeps
pulmonary VSMCs relatively hyperpolarized.31,32 In the cor-
onary circulation, hydrogen peroxide (H2O2) has been proposed
as the signal closely coupling cardiac metabolism to coronary
blood flow33–35 and this coupling appears via H2O2-mediated
augmentation of Kv1.5.19 Recombinant Kv1.5 activity has also
been demonstrated to be directly augmented by H2O2.
36
An additional modulator of Kv1.5 is nitric oxide (NO), a long-
established, biologically active signalling molecule in the
cardiovascular system as well as other tissues.37–39 NO
regulates Kv1.5 via nitrosylation and activation of cGMP,30 an
effect which is of potential importance in the context of AF,
given the important role of this channel in atrial electrical
activity, and also the fact that NO bioavailability is reduced in
AF and NO synthases (NOSs) can become uncoupled,
leading to superoxide formation.38,40,41
Accumulating data continue to establish carbon monoxide
(CO) as an important gasotransmitter alongside NO (and
hydrogen sulphide), which acts to provide a range of beneficial
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cardiovascular (and other) effects. All three of these gaso-
transmitters are products of distinct, widely distributed
enzymes.42,43 CO dilates coronary and other vessels44–46
and induction of heme oxygenase-1 (HO-1, which produces
CO) protects against, for example, myocardial infarction,
hypertension and vascular injury.47,48 CO accounts for many
of the effects of HO-1 induction49–51 and CO inhalation, aswell
as CO-releasingmolecules (CORMs), are being developed for
cardiovascular therapy.52,53 Importantly, HO-1 expression is
increased in AF and appears to provide protection against the
oxidative stress of this condition.54–56 Given the important role
for Kv1.5 in normal atrial function, its redox sensitivity and the
likely involvement of HO-1 as a means of providing protection
in AF, we have explored the potential for CO-mediated
regulation of Kv1.5 channels using both a recombinant
expression system and murine atrial (HL-1) cells.
Results
CO inhibits recombinant human Kv1.5. To examine any
potential modulation of Kv1.5 by CO, we applied the CORM,
CORM-2, to HEK293 cells stably expressing human Kv1.5
(hKv1.5). As exemplified in the time-series plot of Figure 1a,
CORM-2 caused a reversible inhibition of K+ current
amplitudes, and this was associated with a marked slowing
of activation kinetics (Figure 1c). By contrast, the inactive
form of CORM-2, iCORM, was without significant effect
(Figures 1b and c). Inhibition of hKv1.5, and the associated
slowing of kinetics, was seen throughout the range of
activation test potentials employed (up to +80 mV;
Figure 1d). A concentration–response relationship was
constructed using time-series recordings as exemplified in
Figure 1a, which yielded an IC50 value of 23 μM for CORM-2
inhibition of hKv1.5 (Figure 1e).
CO can regulate ion channels via modulation of numerous
signalling pathways.57 To investigate the mechanism of
regulation of hKv1.5 by CO, we first explored the involvement
of ROS. Figures 2a and b indicate that the ability of CORM-2 to
inhibit hKv1.5 was significantly suppressed by a pretreatment
of cells (1 h at 37 °C) with either the reducing agent
dithiothreitol (DTT, 1 mM) or each of two superoxide dismutase
(SOD) mimetics, 5,10,15,20-tetrakis(1-methylpyridinium-4-
yl)-21H,23H porphyrin manganese (III) pentachloride
(MnTMPyP; 50 μM), and manganese (III) tetrakis (4-benzoic
acid) porphyrin chloride (MnTBAP; 10 μM). All three of these
agents significantly, but incompletely, reversed the inhibitory
actions of CO, strongly suggesting that ROS contributed to
CO-mediated inhibition of hKv1.5. To explore the source of
ROS involved in CO-mediated inhibition of Kv1.5, cells were
pretreated (1 h at 37 °C) with either diphenylene iodonium
(DPI; 3 μM), a non-selective inhibitor of NADPH oxidases, or
allopurinol (1 μM), a xanthine oxidase inhibitor. Neither agent
altered the ability of CORM-2 to inhibit hKv1.5 (Figures 2c
and d). By contrast, pretreatment of cells with mitoTEMPO
(10 μM), a mitochondrially targetted antioxidant, almost fully
reversed the inhibitory effects of CO (Figures 2c and d).
Inhibition of hKv1.5 by CO was also significantly reduced
following pretreatment with antimycin A, which inhibits
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Figure 1 CO inhibits recombinant hKv1.5. (a) Time-series plot (generated by repeated step depolarizations from− 80 to +50 mV (100 ms duration, 0.2 Hz)) obtained from a
HEK293 cell stably expressing human Kv1.5 (hKv1.5). Plot shows normalized peak current amplitudes. For the period indicated by the horizontal bar, the cell was exposed to
30 μM CORM-2. (b) As in panel (a), except this cell was exposed to 30 μM iCORM (inactive breakdown product of CORM-2), as indicated. (c) Example currents from the plotted
time series evoked before and during application of CORM-2 (upper) and iCORM (lower). (d) Left, currents evoked in a HEK293 cell expressing hKv1.5 before and during
exposure to 30 μM CORM-2, as indicated. Currents were evoked by step-depolarizations from − 60 to +80 mV. Right, Mean (±S.E.M., n= 6) current–density versus voltage
relationships obtained before (open symbols) and during (solid symbols) application of 30 μMCORM-2. (e) Concentration–response curve for CORM-2 inhibition of hKv1.5. Each
point is the mean (±S.E.M., n= 3–17 cells in each case) fractional inhibition caused by CORM-2. Data fit yields IC50 of 23 μM
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complex III of the electron transport chain (Figures 2c and d).
Thus mitochondria appear to be the source of ROS involved in
CO-mediated inhibition of hKv1.5.
CO is also known to activate NOS and soluble guanylyl
cyclase (sGC) in several cell types. Pretreatment of cells (1 h
at 37 °C) with the NOS inhibitor L-NAME (1 mM) significantly
attenuated the ability of CORM-2 to inhibit hKv1.5 (Figures 2e
and f). Similarly, pretreatment of cells (1 h at 37 °C) with
the membrane-permeable sGC inhibitor, Rp-8-Br-cGMPS
(100 nM), significantly reduced the inhibitory effects of
CORM-2 on hKv1.5 (Figures 2e and f). Pretreatment of cells
with both agents similarly reduced the ability of CO to inhibit
currents (Figures 2e and f). These data suggested that CO
could stimulate NO formation and this was further confirmed
by monitoring NO levels in hKv1.5-expressing HEK293 cells
using the NO-sensitive fluoroprobe, DAF-2 (Figures 3a and b).
Application of CORM-2 (30 μM) to DAF-2-loaded cells caused
a significant rise in fluorescence, which was fully attenuated
following preincubation of cells with 1 mM L-NAME (1 h, 37 °
C). It is likely, therefore, that CO inhibits hKv1.5 in part via
activation of NO formation, as a previous study has suggested
that NO can inhibit Kv1.5.30 NO inhibition was shown by
Nunez et al.30 to be mediated partly via PKG-dependent
phosphorylation, as is the case for CO (Figure 3), and also by
nitrosylation. To explore nitrosylation as a mechanism for CO-
mediated inhibition of hKv1.5, we employed the biotin-switch
technique and detected nitrosylation of hKv1.5 protein by
CORM-2 but not by iCORM (Figure 3c), indicating that CO
does indeed stimulate nitrosylation of hKv1.5.
The observation that CO raises ROS levels (presumably
levels of superoxide, as SODmimetics ameliorated the effects
of CO; Figure 2), and also raises NO levels suggests the
possibility that peroxynitrite (ONOO−) formation occurs in the
presence of CO, as we have previously suggested.58 In
support of this idea, we found that CO increased the level of
fluorescence in cells loaded with the ONOO− indicator, 2-[6-
(4’-amino) phenoxy-3H-xanthen-3-on-9-yl]benzoic acid (APF;
Figure 4a). These rises were fully attenuated by both L-NAME
and the ONOO− scavenger, FeTPPS (Figures 4a and b).
Furthermore, pretreatment of cells with FeTPPS strongly
attenuated the CO-mediated inhibition of hKv1.5 (Figure 4c).
Exploring the roles of C346 and C331. Based on structural
modelling, it has previously been suggested (but not
demonstrated) that two cysteine (C) residues within hKv1.5
might be nitrosylated by NO and thereby account for its
inhibitory action on the channel.28 As much of the effects of
CO, as reported here, are mediated by NO formation
(Figures 2 and 3), we explored the potential involvement of
these two residues, C331 and C346. To do this, we generated
C→A (alanine) substitution mutants. As shown in Figure 5,
CO was still able to inhibit the activity of the C331A
(Figure 5a) and C346A mutant channels (Figure 5b). The
degree of inhibition caused by 30 μM CORM-2 (44± 8.6%,
mean±S.E.M., n=5, Po0.001 for C331A and 47± 1.7%,
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Figure 2 CO inhibition of hKv1.5 involves mitochondrial reactive oxygen species,
NO and soluble guanylyl cyclase. (a) Example currents evoked in hKv1.5-expressing
HEK293 cells before and during exposure to 30 μM CORM-2. Currents are examples
from time-series studies (as in Figure 1) in which cells were repeatedly depolarized
from −80 mV to +50 mV (100 ms duration, 0.2 Hz)). CORM-2 was applied either to
untreated cells or to cells pretreated for 1 h at 37 °C with DTT (1 mM) MnTMPyP
(50 μM) or MnTBAP (10 μM), as indicated. Scale bars represent 1 nA (vertical) and
50 ms (horizontal) in all cases. (b) Bar graph plotting mean (with S.E.M. bars, from
number of cells indicated) % inhibition caused by CORM-2 in the absence or
presence of the drugs indicated (taken from studies exemplified by current traces).
***Po0.001 (effects of CORM-2 alone when compared with controls); ***Po0.001
(comparing effects of CORM-2 alone with CORM-2 in the presence of drugs
indicated). (c) As in panel (a), except cells were pretreated (1 h at 37 °C) with DPI
(3 μM), allopurinol (1 μM), mitoTEMPO (10 μM) or antimycin A (3 μM), as indicated,
prior to recordings. (d) Bar graph plotting mean (with S.E.M. bars) % inhibition caused
by CORM-2 in the absence or presence of the drugs indicated. **Po0.01, *Po0.05,
comparing the effects of CORM-2 alone or with CORM-2 in the presence of drugs
indicated. Dashed line indicates the mean effect of CORM-2 alone. (e) Example
currents evoked in hKv1.5-expressing HEK293 cells before and during exposure to
30 μM CORM-2. Currents are examples from time-series studies (as in Figure 1) in
which cells were repeatedly depolarized from − 80 to +50 mV (100 ms duration,
0.2 Hz)). CORM-2 was applied either to untreated cells or to cells pretreated with
L-NAME (1 mM; 1 h, 37 °C), Rp-8-Br-cGMPS (50 μM; 1 h, 37 °C) or both agents
together, as indicated. Scale bars represent 1 nA (vertical) and 50 ms (horizontal) in
all cases; except the L-NAME-treated example (vertical scale bar= 0.2 nA). (f) Bar
graph plotting mean (with S.E.M. bars, n numbers indicated in each bar) % inhibition
caused by CORM-2 in the presence of the drugs indicated (taken from studies
exemplified by current traces). Mean effect of CORM-2 alone is indicated by the
dashed line. ***Po0.001, significant difference from inhibition caused by
CORM-2 alone
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mean±S.E.M., n=5, Po0.001 for C346A) was not signifi-
cantly different from the degree of inhibition seen in the WT
(non-mutant) hKv1.5 channel. Furthermore, we could detect
nitrosylation of both mutants using the biotin-switch technique
(Figure 5c). These findings discount both C331 and C346 as
important residues in the response of hKv1.5 to CO or NO.
CO reverses H2O2 augmentation of Kv1.5. The activity of
both native and recombinant Kv1.5 channels has been
shown to be augmented by H2O2,
32,36 and this has been
proposed as a mechanism by which cardiac metabolism is
linked to coronary blood flow.33–35 In agreement with these
studies, we found that H2O2 (300 μM) augmented Kv1.5
activity. This effect was fully reversed by CORM-2 (30 μM), as
exemplified in Figure 6a and quantified in Figure 6b. Given
the partial prevention of the effects of CO by mitoTEMPO and
SOD mimetics, this result suggests that H2O2 augmentation
of Kv1.5 is an effect strikingly distinct from the formation of
superoxide or ONOO− that contribute to CO inhibition of the
channel.
Effects of CO in HL-1 atrial cells. To examine the potential
for modulation of native Kv1.5 by CO, we employed the
atrial cell line, HL-1.59 Using a voltage protocol designed
to isolate IKur (which is attributable to Kv1.5 activity), step-
depolarizations evoked outward K+ currents that were
strongly reduced in amplitude by the Kv1.5 inhibitor DPO-1
(1 μM; Figure 7a).60 These currents were also inhibited by
CORM-2 (Figure 7b), suggesting that CO could inhibit native
Kv1.5 channels in HL-1 cells, as it does recombinant Kv1.5
channels. Indeed, 30 μM CORM-2 caused a 49.8± 5% (n= 9)
inhibition of currents at +50 mV, an effect quantitatively similar
to that observed for recombinant channels (Figure 1).
Furthermore, CORM-2 also evoked a measurable rise in
NO levels in HL-1 cells, an effect that was effectively inhibited
by L-NAME (Figure 7c), thereby suggesting an important role
for NO in the actions of CO not only in HL-1 cells but also in
HEK293 cells expressing hKv1.5.
Under current-clamp conditions, we also recorded sponta-
neous action potentials in HL-1 cells. We found that CORM-2
(30 μM) significantly increased action potential amplitudes and
also increased their duration (Figures 8a and c). Importantly, a
similar effect was seen when HL-1 cells were exposed to
DPO-1 (Figures 8b and c). Furthermore, in the presence of
DPO-1, CORM-2 did not increase the amplitude or duration of
currents further (Figures 8b and c), suggesting that both CO
and DPO-1 acted at the same site, Kv1.5. These findings
suggest that CO inhibition of Kv1.5 may be physiologically
significant for atrial excitability.
Discussion
The present study demonstrates that both native and
recombinant hKv1.5 K+ channels are inhibited by CO. This
finding adds to the growing understanding of the complexity of
CO signalling in cardiac and other tissues by describing a new
ion channel target for regulation.57,61,62 Significantly, it also
demonstrates, for the first time, a polymodal means of channel
regulation by CO that is summarized in Figure 8d. Previously,
we have shown that CO-mediated augmentation of the late
cardiac Na+ current is NO dependent and involves channel
nitrosylation.63 Peak inward Na+ current inhibition by CO is
also NO dependent.64 Inhibition of the cardiac L-type Ca2+
current by CO is dependent on mitochondrial ROS production
but independent of NO formation.65 Most recently, we have
shown that cardiac ERG (Kv11.1) channels are also inhibited
by CO, specifically via the formation of ONOO−.66 The present
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Figure 3 CO stimulates NO formation and nitrosylation of hKv1.5. (a) Mean (±S.
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study indicates that Kv1.5 is uniquely inhibited by CO acting
via all of the aforementioned pathways as well as via cGMP
formation, which presumably modifies channel activity via
phosphorylation as suggested previously for the effects of
NO.30
Each of these distinct means of Kv1.5 regulation by CO can
be regarded as potentially important under varying physiolo-
gical and pathological conditions, not only in the heart but also
in the vasculature. Recent studies have provided evidence
that H2O2 generated by cardiac myocytes couples cardiac
metabolism to coronary flow by activating Kv1.5 channels in
coronary VSMCs, which presumably leads to their relaxation
(and hence vessel dilation) due to hyperpolarization and
reduced Ca2+ influx.33–35 CO raises ROS levels, yet reverses
augmentation of Kv1.5 by H2O2 (Figure 6). This would suggest
that ROS contributing to Kv1.5 inhibition by CO are likely to be
either superoxide derived from mitochondria and/or ONOO−
formed from superoxide and NO. It is clear that these ROS
contribute to channel inhibition, whereas H2O2 has the
opposite effect of augmenting current amplitudes – this
suggests that Kv1.5 is differentially regulated by different
oxidant species. Interestingly, CO-mediated inhibition of
hKv1.5 was partly attenuated by the SODmimetics MnTMPyP
and MnTBAP (Figure 2). These agents would presumably
increase H2O2 levels through superoxide dismutation, yet CO
reversed the effects of exogenous H2O2 (Figure 6). This
finding would suggest that CO-mediated inhibition of Kv1.5 via
other mechanisms (e.g., nitrosylation or the sGC/cGMP
pathway) can override augmentation by H2O2. This in turn
suggests that CO levels may physiologically regulate H2O2-
mediated coupling of coronary blood flow to cardiac
metabolism.
Figures 2 and 3 indicate that NO formation has an important
role in Kv1.5 inhibition by CO. Our findings in this regard are
consistent with the study of Nunez et al.30 who demonstrated
that NO inhibited recombinant hKv1.5 via nitrosylation and a
cGMP-dependent mechanism. The present study shows that
CO also activates these pathways by stimulating a rise in NO
levels. However, NO formation does not account for all of the
effects of CO as detailed here. Although molecular modelling
suggested C331 and C346 as candidate cysteine residues for
nitrosylation,30 we found that both the C331A and C346A
mutants remained sensitive to inhibition by CO (Figure 5).
Furthermore, both mutant channels were nitrosylated by CO,
suggesting that alternative cysteines in the Kv1.5 channel are
preferentially targeted for nitrosylation. Physiologically, this
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NO-dependent means by which CO regulates Kv1.5 activity is
likely to be important both in the vasculature (particularly but
not exclusively the coronary vasculature, as discussed above)
and in the heart, where Kv1.5 exerts an important influence in
shaping the atrial AP.20,21 Kv1.5 is an important target for
therapies aimed at treating AF,23,25 and interestingly, main-
tenance or augmentation of NO bioavailability is also
considered a viable approach in the treatment of AF.41 Our
data suggest that increasing CO levels (either via stimulating
HO-1 expression or via CO donors53) may therefore be of
benefit in AF treatment via increased NO formation. However,
elevated NO in the presence of superoxide can lead to the
formation of ONOO− and this was indeed observed in our
study (Figure 4). ONOO− formation is seen in AF67,68 and is
presumably deleterious. Increased ONOO− formation con-
tributes to shortening of the effective refractory period seen in
AF, but this is unlikely to arise from inhibition of Kv1.5, as this
would be expected to prolong AP duration and therefore,
presumably, the effective refractory period.
A noteworthy feature of the CO-mediated inhibition of Kv1.5
was the marked slowing of its activation kinetics (see
Figure 1d), which was also prominent in the mutants
(Figure 5). Slowing of activation by CO appears strikingly
similar to the previously reported slowing of activation caused
by zinc.69 It would appear that this effect cannot be attributed
to any particular single pathway of channel inhibition because
residual inhibition caused by CO in the presence of SOD
mimetics, NO or sGC inhibition or in the presence of FeTPPS
to scavenge ONOO− was not associated with a slowing of
channel activation. This suggests that a combination of these
signalling pathways is required in order to observe kinetic
changes caused by CO together with channel inhibition.
To explore CO-mediated modulation of Kv1.5 in a more
physiological setting, we investigated its ability to regulate K+
currents in the mouse atrial cell line, HL-1. Our data indicate
that CO inhibits a DPO-1-sensitive K+ current in these cells
and so presumably arises at least primarily due to activity of
Kv1.5.60 Our data do not exclude actions of CO on other
cardiac ion channels, and indeed a number of such channels
are known to be CO sensitive.61 However, inhibition of Kv1.5
does appear to be of functional significance, as it significantly
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Figure 5 Mutation of C331 or C346 does not impede CO-mediated inhibition of
hKv1.5. (a) Time-series plot (generated by repeated step-depolarizations from −80
to +50 mV (100 ms duration, 0.2 Hz)) obtained from a HEK293 cell stably expressing
hKv1.5 containing the C331A mutation. Plot shows normalized peak current
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and mutant hKv1.5 channels was detected using the biotin-switch assay. Note:
nitrosylation of hKv1.5 was only detected in samples treated with CORM-2,
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increased AP amplitude and duration in a manner that was
bothmimicked and occluded byDPO-1. Thus CO regulation of
Kv1.5 is potentially of physiological significance for regulating
atrial excitability. It may also be of pathological significance, for
example, in atrial fibrillation, which is associated with
increased expression of HO-1.54,56
In summary, we have demonstrated that CO inhibits both
native (mouse) and recombinant (human) Kv1.5 and does so
via multiple signalling pathways. Tonic regulation of Kv1.5 by
CO is likely to be of physiological relevance in cardiac atria as
well as vascular smooth muscle, where it may regulate
channel responses to other signalling factors (e.g., H2O2).
The significance of Kv1.5 regulation by CO may increase
under pathological conditions such as atrial fibrillation and
vascular disease due to increased HO-1 expression.
Materials and Methods
Generation and culture of HEK293 cells expressing Kv1.5. Wild-
type (WT) human Kv1.5 (KCNA5) cDNA was amplified from a human foetal brain
cDNA library (Clontech, Wooburn Green, Buckinghamshire, UK) using the primers:
5′-TGGAATTCACCATGGAGATCGCCCTG-3′ and 5′-GACTCGAGTCACAAATCTG
TTTCCCG-3′ (Sigma-Aldrich, Gillingham, Dorset, UK) in a touchdown PCR. The
≈1.7 kb product was cloned using the CloneJET Kit (Thermo Fisher Scientific,
Loughborough, Leicestershire, UK) and then subcloned into pcDNA6 (Invitrogen,
Loughborough, Leicestershire, UK) using EcoRI and XhoI restriction enzymes (New
England Biolabs, Hitchin, Hertfordshire, UK). At each step, clones were confirmed
by Sanger sequencing (Genewiz, Bishop’s Stortford, Hertfordshire, UK).
HEK293 cells were cultured in MEM with Earle’s salts and L-glutamine,
supplemented with 9% (v/v) fetal calf serum (Globepharm, Esher, Surrey, UK), 1%
(v/v) non-essential amino acids, 50 μg/ml gentamicin, 100 units/ml penicillin G,
100 μg/ml streptomycin and 0.25 μg/ml amphotericin in a humidified atmosphere of
air/CO2 (19 : 1) at 37 °C. All cell culture reagents were purchased from Gibco-BRL
(ThermoFisher Scientific) unless otherwise stated. To generate stable HEK293/Kv1.5
cell lines, cells were transfected with either a pcDNA6/Kv1.5(WT) or pcDNA6/Kv1.5
(Mutant) construct using the PolyFect transfection reagent (Qiagen, Hybaid Ltd,
Teddington, UK) according to the manufacturer’s instructions. Stable HEK293/Kv1.5
cell lines were achieved by antibiotic selection with blasticidin (5 μg/ml, ThermoFisher
Scientific), added to the medium 3 days after transfection. Selection was applied for
4 weeks (media changed every 4–5 days), after which time individual colonies were
picked and seeded in T25 flasks and allowed to reach confluence. They were then
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Figure 7 CO inhibits native K+ currents and raises NO levels in HL-1 atrial cells. (a) Families of outward K+ currents recorded in an example HL-1 cells by step-depolarizations
as described in Methods section, before (control) and during (DPO-1) bath application of the Kv1.5 inhibitor, DPO-1 (1 μM). Right, mean (± S.E.M., n= 7 cells) current density
versus membrane potential plot before (solid symbols) and during (open symbols) application of 1 μM DPO-1. (b) Exactly as in panel (a), except cells were exposed to CORM-2
(30 μM; n= 9) rather than DPO-1. (c) Left, mean (±S.E.M.) fluorescence recorded in HL-1 cells loaded with the NO indicator, DAF-2. Fluorescence was measured in untreated
cells (open circles, n= 5) or cells pretreated with L-NAME (1 mM; solid circles; 1 h, 37 °C; n= 5). Right, example images at 0 and 10 min after commencement of CORM-2
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transferred to T75 flasks for further culture and examination of K+ currents. Cells were
harvested from culture flasks by trypsinization and plated onto coverslips 24–48 h
before use in electrophysiological studies. Blasticidin selection was maintained
throughout the entire cloning process at 5 μg/ml and then subsequently reduced to
2.5 μg/ml in all subsequent passages of cells once stable clones had been positively
identified.
The C331A and C346A mutations were introduced into WT human Kv1.5 (hKv1.5,
in pcDNA6) using the Quik-Change Site-Directed Mutagenesis Kit (Stratagene,
Cheadle, UK) according to the manufacturer’s instructions. All constructs were
verified by DNA sequence analysis before transfection.
Culture of HL-1 cells. HL-1 atrial cardiomyocytes were maintained in
Claycomb media (Sigma, UK) supplemented with batch-specific 10% FBS (Sigma,
Gillingham), 1% penicillin/streptomycin (Invitrogen), 0.1 mM norepinephrine (Sigma)
and 2 mM l-glutamine (Invitrogen). Cells were cultured in flasks, or on coverslips,
pretreated with 0.02% Bacto gelatin (Fisher Scientific, Loughborough, UK) and 0.5%
fibronectin (Invitrogen).
Exposure to CO. CO was applied to HEK293 cells and HL-1 cells via the
CORM, CORM-2. CORM-2 was prepared no longer than 1 h before use by
dissolving in dimthylsulphoxide (DMSO) at a stock concentration of 30 mM so that
dilution into perfusate or other solutions in which cells were maintained (e.g.,
electrophysiology, imaging, biotin switch assay) usually resulted in DMSO levels of
no more than 1 : 1000. iCORM, which served as a negative control, was prepared
by dissolving CORM-2 identically and leaving in perfusate solution for 2 weeks prior
to use, by which time all CO was released and lost from solution.
Electrophysiology. Coverslips with cultured cells were transferred from the
incubator into a recording chamber mounted on the stage of an Olympus CK40
inverted microscope (Olympus, London, UK) and continually perfused with bath
solution (2–4 ml.min–1) containing the following: 140 mM NaCl, 4 mM KCl, 2 mM
CaCl2, 1 mM MgCl2, 5 mM glucose, buffered with 10 mM HEPES, pH 7.4. Single
cells were selected for whole-cell patch-clamp experiments at 22± 1 °C. Pipettes
were filled with intracellular solution (140 mM KCl, 10 mM NaCl, 4 mM MgCl2,
20 mM EGTA, 10 mM HEPES, pH 7.2) and had a resistance of 4–6 MΩ. Whole-cell
voltage-clamp or current-clamp experiments were recorded, digitized and stored
with an Axopatch 200B amplifier, Digidata 1322A and pCLAMP 10 respectively
(Molecular Devices, Union City, CA, USA).
Series resistance was compensated by 70–90%. If a significant increase in series
resistance occurred (420%), the experiment was terminated. Leak currents were
subtracted using the P/4 protocol in the pCLAMP software and voltage-clamp signals
were sampled at 50 kHz and low-pass filtered at 20 kHz; I–V relationships were
measured by stepping from a holding potential of − 90 mV to voltages between − 60
and +80 mV in 10 mV increments for 500 ms. Time-series experiments were
measured using a single pulse protocol stepping from − 90 to +50 mV for 100 ms
every 5 s.
HL-1 spontaneous APs were acquired in gap-free mode with no current injected.
IKur was recorded as described previously
70 using a 100 ms prepulse to +40 mV to
inactivate Ito1, followed by a 150 ms test pulse from − 50 to between − 40 and +50,
then to − 30 mV.
Offline analysis was performed using the data analysis package Clampfit 10.0
(Molecular Devices, Foster City, CA, USA), and subsequent fitting and statistical
analysis was undertaken using GraphPad Prism 7 (GraphPad Software, La Jolla, CA,
USA). Results are presented as means± S.E.M., with ‘n’ representing the number of
experiments performed. Statistical significance was evaluated using unpaired
Student’s t‐tests where differences were considered significant when the P-value was
o0.05.
Biotin-switch assay. Detection of S-nitrosylated hKv1.5 was performed using
the biotin-switch assay followed by western blotting as previously described.71
Briefly, HEK293 cells expressing WT or mutant (C331A or C346A) Kv1.5 were
harvested and lysed in a non-denaturing solution (in mM: 50 Tris-HCl, 300 NaCl,
5 EDTA, and 1% Triton-X). Extracts were adjusted to 0.5 mg/ml and incubated with
CORM-2 (30 μM) for 15 min at 37 °C; inactive CORM (iCORM, 30 μM) and DMSO
were used as controls.
CORM-2 and iCORM were removed and buffered exchanged using desalting spin
columns (Thermo Fisher Scientific). From this point, all procedures were carried out in
the dark. Lysates were incubated in blocking buffer (in mM: 225 HEPES, 0.9 EDTA, 20
methyl methanethiosulfonate (MMTS), and 2.5% SDS, pH 7.4) for 20 min at 50 °C
with agitation. Lysates were subjected to buffer exchange to remove MMTS and
eluted in HENS buffer (mM: 250 HEPES, 1 EDTA, and 1% SDS, pH 7.4) and
incubated with 1/3 volume of N-[6-(biotinamido)hexyl]-3′-(2′-pyridyldithio) propiona-
mide (biotin-HPDP, Pierce, Loughborough, UK) and ascorbate (1 mM) for 1 h at room
temperature, followed by buffer exchange to remove biotin–HPDP from the samples.
Unless otherwise stated, all buffers were supplemented with protease inhibitor
cocktail tablets (Roche, Welwyn Garden City, UK).
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Figure 8 CO augments action potentials in HL-1 cells. (a) Spontaneous action
potentials (APs) recorded in an example HL-1 cell before (control) and during
application of 30 μM CORM-2. Note: CORM-2 increases the AP amplitude and
duration. (b) As in panel (a), except that the cell was exposed to DPO-1 (1 μM), then
CORM-2 (30 μM) in the continued presence of DPO-1. Note: DPO-1 augments APs
and prevents further augmentation by CORM-2. (c) Mean (±S.E.M.) augmentation
in AP amplitude (AP amp.; left) and APD50 (right) caused by CORM-2 alone (n= 10),
DPO-1 (n= 9) alone or CORM-2 in the continued presence of DPO-1 (both; n= 8).
Significant difference from control (no drug): ***Po0.001, **Po0.01, *Po0.05.
There were no significant differences between the conditions. (d) Schematic
mechanism for the inhibition of Kv1.5 by CO. Data presented suggest CO increases
ROS (presumably superoxide, O2
−) formation from mitochondria, which may
directly regulate Kv1.5, but can also combine with NO (levels of which increase in
response to CO) to form peroxynitrite (ONOO−) to cause channel inhibition.
Elevated NO levels also directly nitrosylate Kv1.5. CO can also stimulate sGC (an
effect that is also promoted by elevated NO levels), which leads to channel
phosphorylation
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Biotinylated proteins were detected via western blotting as described previously.28
Protein samples were prepared without reducing agents and were not boiled before
electrophoresis to prevent the reversal of cysteine biotinylation and non-specific
biotin–HPDP reactions, respectively.
Fluorescence detection of nitric oxide (NO) and peroxynitrite
(ONOO−). Cells were plated on coverslips and allowed to grow for 48 h at 37 °C
in a humidified atmosphere containing 95% air and 5% CO2 before being
preincubated for 1 h with DAF-2 diacetate (5 μM; Invitrogen), prepared in the
following extracellular solution: 140 mM NaCl, 4 mM KCl, 1.5 mM CaCl2, 2 mM
MgCl2, 10 mM HEPES, 10 mM glucose, pH 7.4). Cells were then gently washed
twice with extracellular solution and then left for at least 15 min in an incubator to
allow the hydrolysis of DAF-2 diacetate into the free NO-sensitive free acid form
(DAF-2).
Fragments of coverslip with attached cells were placed on a Zeiss (Oberkochen,
Germany) laser scanning confocal microscope (LSM 510) fitted with a × 40 oil
immersion lens (Zeiss Plan Neofluar, refractive index of 1.3) and continuously
perfused with extracellular solution at a rate of 0.5 ml/min. DAF-2 loaded cells were
excited with the 488-nm line of a 20-mW diode laser (attenuated by ∼ 90%), and
emitted fluorescence was measured at4515 nm. x–y images were obtained from
isolated cells at 1 min intervals to minimize photobleaching using the Zeiss AIM
software. Experimental settings were identical in all test conditions and each
experiment was repeated five times. Fluorescence intensity of isolated cells was
analysed using the ImageJ software (Laboratory for Optical and Computational
Instrumentation, Madison, WI, USA) and data are presented as means±S.E.M.
To detect ONOO−, cells grown on coverslips were incubated for 1 h at 37 °C with
APF (10 μM) dissolved in HEPES-buffered saline. For L-NAME or FeTPPS
experiments, cells were preincubated with either drug at the same time as the APF
treatment. Coverslips fragments with cells attached were placed in a chamber (as a
static bath set-up) filled with 200 μl of HEPES-buffered saline containing 10 μM APF.
Changes in fluorescence intensity were measured over 10 min using a ZEISS
(Oberkochen) laser-scanning confocal microscope (LSM 510). APF was excited at
488 nm and emission monitored at 510 nm, and images were obtained using the
Zeiss AIM software. All settings were identical for control and test conditions.
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